The global dermatological (prescription) drugs market was valued at $38.4bn in 2017, this figure is set to rise to $44.1bn across 2018, according to a new report published today by GMR Data - The Global Dermatology Market to 2028.

In addition GMR Data forecasts that the global dermatology (prescription) drugs market will report a CAGR of 6.4% between 2018 and 2028.


Of the seven dermatological drugs types / segments highlighted in the report, Atopic Dermatitis and Skin Cancer are estimated to display the highest growth rates (10-year CAGR) of 12.8% and 9.2% respectively.

GMR Data attributes this growth to a change in treatment modalities of the mentioned dermatological diseases. The new treatment modality widely uses a targeted approach of ‘biological’ drugs that are specific, highly efficacious and result in high QALY; for instance - MoAbs or monoclonal antibodies witnessed higher adoption rates in Atopic Dermatitis.

Included in thereport is analysis of the leading companies and geographies in the dermatology drugs market, as well as of the opportunities and threats facing manufacturers. The report has forecasts for all key submarkets in the market as well as for the leading drugs.

The primary companies in the market are studied with pipeline products and merger & acquisitions in relation to the dermatology sector.

This independent, 180 page report guarantees you will remain better informed than your competition. With over 150 tables and figures examining the dermatology drugs market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2028, which keeps your knowledge that one step ahead, helping you to succeed.

This report is essential reading for you or anyone in the pharmaceutical or health care sectors. Purchasing this report today will help you to recognise those important market opportunities and understand the possibilities there.


To order this report today get in touch via or head to